权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel multispectral optoacoustic tomography contrast agents for evaluation of early response to radiation therapy

用于评估放射治疗早期反应的新型多光谱光声断层扫描造影剂

基本信息

批准号：
10325485
负责人：
Joshua Akhigbe
金额：
$ 40万
依托单位：
NIRVANA SCIENCES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-22 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10325485
关键词：
Address Albumins Algorithms Animal Model Animals Binding Biochemical Biodistribution Biological Markers Blood Blood Vessels Cancer Center Color Contrast Media Development Evaluation Exhibits Foundations Goals Human Hydrophobicity Hypoxia Image Imaging technology In Vitro Indocyanine Green Injections Kinetics Lethal Dose 50 Malignant Neoplasms Measurement Measures Modeling Modification Pathologic Patients Performance Perfusion Phase Polyethylene Glycols Protocols documentation Radiation therapy Research Resolution Scanning Science Signal Transduction Small Business Innovation Research Grant Solid Solid Neoplasm Technology Tissues Vascular Permeabilities absorption biomaterial compatibility cancer imaging chemotherapeutic agent clinical translation commercialization contrast enhanced cytotoxicity design hydrophilicity imaging modality improved in vivo innovation insight light scattering multiplexed imaging novel optoacoustic tomography pancreatic cancer model particle pharmacokinetic model photoacoustic imaging predicting response public health relevance quantitative imaging radiation response response scale up small molecule temporal measurement tumor tumor xenograft water solubility

项目摘要

Project Summary/Abstract Vascular perfusion is a useful biomarker for assessment of many pathological conditions. Our research will focus on development of superior contrast agents for use with Dynamic Contrast Enhanced (DCE) Multi- Spectral Optoacoustic Tomography (MSOT; also known as photoacoustic imaging (PAI)) to quantitatively measure changes in this parameter to measure early response of solid tumors to radiation therapy. This emerging imaging technology provides outstanding temporal resolution that is critical for estimating kinetic perfusion rates while also providing excellent spatial resolution. However, existing contrast agents for this imaging modality possess serious performance limitations. NIRvana Sciences, Inc. proposes to develop a new contrast agent with enhanced performance in DCE MSOT. This will include modification of existing hydrophobic designs to optimize their water solubility, biocompatibility, and biodistribution attributes for in vivo use. NIRvana’s agents possess sharp, narrow absorption bands in the near-infrared (NIR) spectral window and offer the first multi-color palette of spectrally resolvable narrow spectrum agents for multiplex imaging with MSOT with greater sensitivity. These contrast agents will provide outstanding innovations for evaluation of changes in tumor perfusion by DCE MSOT that can indicate an early response to radiation therapy.

项目概要/摘要血管灌注是评估许多病理状况的有用生物标志物。我们的研究将专注于开发用于动态对比增强 (DCE) 多用途的优质造影剂光谱光声断层扫描（MSOT；也称为光声成像（PAI））测量该参数的变化以测量实体瘤对放射治疗的早期反应。这新兴成像技术提供出色的时间分辨率，这对于估计动力学至关重要灌注率，同时还提供出色的空间分辨率。然而，现有的造影剂成像方式具有严重的性能限制。 NIRvana Sciences, Inc. 提议开发一种新的在 DCE MSOT 中具有增强性能的造影剂。这将包括修改现有的疏水性设计可优化其水溶性、生物相容性和体内生物分布属性使用。 NIRvana 的试剂在近红外 (NIR) 光谱窗口中具有尖锐、窄的吸收带，并且提供第一个光谱可分辨窄谱试剂的多色调色板，用于多重成像 MSOT 具有更高的灵敏度。这些造影剂将为评估提供杰出的创新 DCE MSOT 检测肿瘤灌注的变化可以表明对放射治疗的早期反应。